EX-99.1 2 tenx_ex991.htm PRESS RELEASE EXHIBIT 99.1 Tenax Therapeutics Provides Business and Clinical Development Updates with Full Year 2023 Financial Results · First Patient Enrolled in Phase 3 LEVEL Trial Evaluating TNX-103 (oral levosimendan) for the Treatment of Pulmonary Hypertension from Heart Failure with Preserved Ejection Fraction (PH-HFpEF) · Expansion of U.S. Intellectual Property Covering the Use of Levosimendan for the Treatment of PH-HFpEF and for Use in Combination with Other Cardiovascular ...